Advanced endoscopy in colorectal cancer: Colorectal prostheses

Background and Aims: The dietary inflammatory index (DII) is associated with non-communicable disease. We conducted an umbrella review to systematically evaluate meta-analyses of observational studies on DII and diverse health outcomes.Methods: We comprehensively searched the PubMed, Web of Science, and Embase databases to identify related systematic reviews and meta-analyses of observational studies. Those investigating the association between DII and a wide range of health outcomes in humans were eligible for inclusion. For each meta-analysis, we estimated the summary effect size by using fixed and random effects models, the 95% confidence interval, and the 95% prediction interval. We assessed heterogeneity, evidence of small-study effects, and excess significance bias.Results: The umbrella review identified 35 meta-analyses assessing associations between DII and various health outcomes: cancer (n = 24), mortality (n = 4), metabolic (n = 4), and other (n = 3). The methodological quality was high or moderate. Of the 35 meta-analyses, we observed highly suggestive evidence for harmful associations between digestive tract cancer, colorectal cancer, overall cancer, pharyngeal cancer, UADT cancer, and CVD mortality. Moreover, 11 harmful associations showed suggestive evidence: hormone-dependent cancer, rectal cancer, colon cancer, breast and prostate cancer, gynecological cancer, breast cancer, ovarian cancer, colorectal cancer, prostate cancer, all-cause mortality, and depression.Conclusion: DII is likely to be associated with harmful effects in multiple health outcomes. Robust randomized controlled trials are warranted to understand whether the observed results are causal.Systematic Review Registration: CRD42021218361

Download Full-text

Epidemiology Study for Cancer Incidences among Patients from Baghdad Carrying Different Types of Cancer.

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v9ispl1.1346 ◽

2018 ◽

Vol 9 (SPL1) ◽

Author(s):

Dawood Salim Edan ◽

HamedH Khamees

Keyword(s):

Breast Cancer ◽

Colorectal Cancer ◽

Bladder Cancer ◽

Endometrial Cancer ◽

Cancer Colorectal ◽

Cancer Epidemiology ◽

The Other ◽

Epidemiology Study ◽

Different Types ◽

Prevalence Of Cancer

This study was carried out in Al-Yarmook hospital,laboratories department,Baghdad- Iraq; One hundred thirty three Iraqi patients have been recorded during period May 2014 until December 2014.The current study has demonstrated that five different types of the following cancers: Breast cancer,Skin cancer,colorectal cancer,Bladder cancer and endometrial cancer were enrolled in this study. Comparison among each type of cancer was regarded in age, sex and number. The majority results in cancer epidemiology for the present study were fluctuated between the skin and breast cancer,which showed 33.1% and this,represented the prevalence of cancer among all the other types of cancers. In case of other types,the result has showed 16.5 %,13.5% and 3.7 % for endometrial cancer,Bladder cancer and colorectal cancer,respectively.

Download Full-text

A Review on the Carcinogenic Roles of DSCAM-AS1

Frontiers in Cell and Developmental Biology ◽

10.3389/fcell.2021.758513 ◽

2021 ◽

Vol 9 ◽

Author(s):

Soudeh Ghafouri-Fard ◽

Tayyebeh Khoshbakht ◽

Mohammad Taheri ◽

Kaveh Ebrahimzadeh

Keyword(s):

Breast Cancer ◽

Colorectal Cancer ◽

Antisense Rna ◽

Breast Tumor ◽

Cancer Colorectal ◽

Small Cell ◽

Small Cell Lung ◽

Breast Tumor Cells ◽

Non Coding Rnas

Long non-coding RNAs (lncRNAs) are a group of transcripts with fundamental roles in the carcinogenesis. DSCAM Antisense RNA 1 (DSCAM−AS1) is an example of this group of transcripts which has been firstly identified in an attempt to find differentially expressed transcripts between breast tumor cells and benign breast samples. The pathogenic roles of DSCAM-AS1 have been vastly assessed in breast cancer, yet its roles are not restricted to this type of cancer. Independent studies in non-small cell lung cancer, colorectal cancer, osteosarcoma, hepatocellular carcinoma, melanoma and cervical cancer have validated participation of DSCAM-AS1 in the carcinogenic processes. miR-577, miR-122-5p, miR-204-5p, miR-136, miR−137, miR−382, miR−183, miR−99, miR-3173-5p, miR-874-3p, miR-874-3p, miR-150-5p, miR-2467-3p, miR-216b, miR-384, miR-186-5p, miR-338-3p, miR-877-5p and miR-101 are among miRNAs which interact with DSCAM-AS1. Moreover, this lncRNA has interactions with Wnt/β-catenin pathway. The current study aims at summarization of the results of studies which focused on the assessment of oncogenic role of DSCAM-AS1.

Download Full-text

Promising Advances in LINC01116 Related to Cancer

Frontiers in Cell and Developmental Biology ◽

10.3389/fcell.2021.736927 ◽

2021 ◽

Vol 9 ◽

Author(s):

Yating Xu ◽

Xiao Yu ◽

Menggang Zhang ◽

Qingyuan Zheng ◽

Zongzong Sun ◽

...

Keyword(s):

Colorectal Cancer ◽

Gastric Cancer ◽

Lung Cancer ◽

Cancer Colorectal ◽

Malignant Tumors ◽

Biological Processes ◽

Aberrant Expression ◽

Protein Coding ◽

Future Studies ◽

Non Coding Rnas

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

Download Full-text

Correlation of negative PD-L1 expression with TMB-H and MSI-H rates.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e13162 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e13162-e13162

Author(s):

Jun Dong ◽

Xiaoni Zhang ◽

Hongyue Qu ◽

Shifu Chen ◽

Ziyang Zhu ◽

...

Keyword(s):

Colorectal Cancer ◽

Protein Expression ◽

Cancer Colorectal ◽

Tumor Mutation Burden ◽

Mutation Burden ◽

Sequencing Library ◽

Expression Evaluation ◽

L1 Protein ◽

Next Generation Sequencing Ngs ◽

Generation Sequencing

e13162 Background: PD-L1 protein expression, tumor mutation burden (TMB) and microsatellite instability (MSI) are majorbiomarkers for PD-1/PD-L1 blockade therapy for solid tumors. We designed a study to evaluate the relevance of these biomarkers. Methods: From April 2018 to December 2018, 197 patients with lung cancer, colorectal cancer, andgastric cancer wereprospectivelyenrolled.Foreachpatient, afreshfrozentissuesampleor FFPE sample wascollected. Each sample was dividedinto3parts for next-generation sequencing (NGS), PD-L1 protein expression evaluation and MSI evaluation. The sequencing library was captured using a 605-gene panel and sequenced at~5,000×coverage.Mutationsinthe NGS datawereidentified,andTMB was then calculated. The PD-L1 protein expression was analyzedby immunohistochemistry, and the MSI was evaluated using a multiplex PCR comprising 5 loci(NR27, NR21, NR24, BAT25, and BAT26). Results: 18.78% (37/197) were detected with high PD-L1 expression (positive tumor cells ≥50%); 5.08% (10/197) ofpatientswere diagnosed as MSI-H; 4.06% (8/197) of patients had a TMB-H (TMB > 20 mutations/Mb). Among the 37 PD-L1 positive patients, only one patientwith TMB-Hwas detected, and 3patients were MSI-H. In contrast, among the 14 patients with PD-L1 expression less than 1%, 8patients (57.14%) were detected with TMB-H or MSI-H (3 with TMB-H only, 3 with MSI-H only, and 2 with both). In addition, among all the 10patients with MSI-H, 4patients had TMB-H, indicating that MSI-H may be partly associatedwith high TMB. Conclusions: From our preliminary result, PD-L1 protein expression negative patients tend to have higher rates of TMB-H and MSI-H. For patients with negative PD-L1 expression, it issuggested to evaluate its TMB level and MSI status. This study is ongoing, and more data will be collected to verify these findings.

Download Full-text